Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 688 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 688 shares of the stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $87.53, for a total transaction of $60,220.64. Following the transaction, the insider owned 216,438 shares of the company’s stock, valued at approximately $18,944,818.14. This represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, July 13th, Jason Adair sold 7,863 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total value of $562,283.13.

Liquidia Stock Down 0.0%

Shares of NASDAQ:LQDA traded down $0.04 during midday trading on Wednesday, reaching $86.78. The company had a trading volume of 1,140,996 shares, compared to its average volume of 1,805,184. Liquidia Corporation has a 1-year low of $16.82 and a 1-year high of $91.10. The stock has a market cap of $7.72 billion, a PE ratio of 619.90 and a beta of 0.55. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The business’s 50 day moving average price is $72.31 and its 200 day moving average price is $50.98.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Research analysts forecast that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

LQDA has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Wells Fargo & Company lifted their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Wall Street Zen cut shares of Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Needham & Company LLC lifted their price target on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $86.18.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of the business. Handelsbanken Fonder AB acquired a new stake in Liquidia in the 2nd quarter worth about $1,993,000. Fulcrum Equity Management acquired a new position in shares of Liquidia during the 2nd quarter worth approximately $399,000. Fluent Financial LLC acquired a new position in shares of Liquidia during the 2nd quarter worth approximately $287,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia during the second quarter worth approximately $1,395,000. Finally, Seven Fleet Capital Management LP raised its position in shares of Liquidia by 124.5% in the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after buying an additional 113,609 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).